A Study in Healthy Men to Test How Bosentan Influences the Amount of Zongertinib in the Blood

Recruiting Phase 1 Interventional Study
Healthy
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
25 – 55
Sex
Male
Trial phase
Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
16 (estimated)
Sponsor
Boehringer Ingelheim · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The main objective of this trial is to investigate the effect of a moderate CYP 3A inducer bosentan on the pharmacokinetics of zongertinib.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion criteria : 1. Healthy male trial participant according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (Blood pressure (BP), Pulse rate (PR)), 12-lead Electrocardiogram (ECG), and clinical laboratory tests 2. Age …
Contacts

Boehringer Ingelheim

1-800-243-0127

clintriage.rdg@boehringer-ingelheim.com

CONTACT